Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
JPY 46.0
(0.0%)
JPY 46.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.33 Billion JPY | -34.6% |
| 2022 | 2.04 Billion JPY | -21.06% |
| 2021 | 2.58 Billion JPY | 2.49% |
| 2020 | 2.52 Billion JPY | -23.31% |
| 2019 | 3.28 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 341.4 Million JPY | -1.5% |
| 2024 Q2 | 324.36 Million JPY | -4.99% |
| 2023 Q3 | 293.15 Million JPY | -5.4% |
| 2023 FY | 1.33 Billion JPY | -34.6% |
| 2023 Q2 | 309.87 Million JPY | -30.91% |
| 2023 Q1 | 448.5 Million JPY | 15.9% |
| 2023 Q4 | 346.6 Million JPY | 18.23% |
| 2022 Q3 | 540.16 Million JPY | 0.0% |
| 2022 FY | 2.04 Billion JPY | -21.06% |
| 2022 Q4 | 386.96 Million JPY | -28.36% |
| 2021 FY | 2.58 Billion JPY | 2.49% |
| 2020 FY | 2.52 Billion JPY | -23.31% |
| 2019 FY | 3.28 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -3.892% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -131.351% |
| GNI Group Ltd. | 9.32 Billion JPY | 85.685% |
| Linical Co., Ltd. | 2.7 Billion JPY | 50.67% |
| Trans Genic Inc. | 2.15 Billion JPY | 38.214% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 10.508% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 56.547% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 28.138% |
| AnGes, Inc. | 8.9 Billion JPY | 85.01% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -41.501% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 93.046% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -223.123% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -36.816% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 48.026% |
| CanBas Co., Ltd. | 278 Million JPY | -380.023% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -16.901% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 26.595% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 16.792% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 43.79% |
| PeptiDream Inc. | 9.68 Billion JPY | 86.225% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 31.936% |
| Ribomic Inc. | 1.1 Billion JPY | -20.691% |
| SanBio Company Limited | 4.53 Billion JPY | 70.6% |
| Healios K.K. | 3.48 Billion JPY | 61.73% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -15.564% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 4.916% |
| StemRIM | 2.07 Billion JPY | 35.719% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 32.036% |
| FunPep Company Limited | 313.82 Million JPY | -325.231% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -39.295% |
| Stella Pharma Corporation | 963.98 Million JPY | -38.432% |
| TMS Co., Ltd. | 943.25 Million JPY | -41.475% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -22.433% |
| Cuorips Inc. | 598.11 Million JPY | -123.111% |
| K Pharma,Inc. | 543.94 Million JPY | -145.332% |
| Takara Bio Inc. | 23.9 Billion JPY | 94.418% |
| ReproCELL Incorporated | 1.51 Billion JPY | 11.859% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -12.709% |
| StemCell Institute Inc. | 1.16 Billion JPY | -14.83% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 12.338% |
| CellSeed Inc. | 804.93 Million JPY | -65.786% |